2012
Drug targets and predictive biomarkers in the management of metastatic melanoma
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics And Personalized Medicine 2012, Volume 5: 139-148. PMID: 23226069, PMCID: PMC3513235, DOI: 10.2147/pgpm.s25100.Peer-Reviewed Original ResearchMetastatic melanomaPredictive biomarkersApproval of ipilimumabChoice of treatmentImmune system characteristicsFederal Drug AdministrationClinical benefitTherapeutic optionsFatal skin cancerTreatment strategiesDrug combinationsMelanoma treatmentPromising drugAntitumor effectsDrug AdministrationSkin cancerIndividual tumorsMelanomaPersonalized therapyTherapyTreatmentDrug targetsBiomarkersIpilimumabTumors
2009
Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. Clinical Cancer Research 2009, 15: 3029-3036. PMID: 19383818, PMCID: PMC4431617, DOI: 10.1158/1078-0432.ccr-08-2768.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsCell ProliferationChromonesEnzyme InhibitorsHumansImmunoblottingImmunoenzyme TechniquesMelanomaMorpholinesNevus, PigmentedPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Array AnalysisSkin NeoplasmsTissue Array AnalysisTumor Cells, CulturedConceptsPhosphatidylinositol-3 kinasePI3K inhibitorsExpression of p85PI3KP110alpha subunitPathway membersK inhibitorsCell linesPI3K pathway membersReverse phase protein arrayGood drug targetPhase protein arrayPI3K pathwayTargets of drugsCellular processesPhospho-Akt levelsPI3K inhibitionMelanoma cell linesDrug targetsFull activationP85K pathwayLY294002Protein arraysResistant cell lines
2007
Assessment of PI3 kinase as a druggable target in melanoma
Aziz S, Pick-Golan E, McCarthy M, Flaherty K, Camp R, Rimm D, Kluger H. Assessment of PI3 kinase as a druggable target in melanoma. Journal Of Clinical Oncology 2007, 25: 8521-8521. DOI: 10.1200/jco.2007.25.18_suppl.8521.Peer-Reviewed Original ResearchPI3-kinaseKinase expressionDrug targetsIntracellular signal transduction pathwaysNumerous cellular functionsSignal transduction pathwaysMajor intracellular signal transduction pathwaysPI3-kinase inhibitorAttractive drug targetValuable drug targetsCellular functionsTransduction pathwaysDifferential expressionBenign neviKinaseDruggable targetsExpression levelsProtein levelsMalignant melanocytesKinase inhibitorsDisease aggressionExpressionMalignant cellsPrimary specimensTarget